Globe Trade Centre Stock
Price
Target price
?
?
3.620%
0.017
3.620%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Globe Trade Centre Stock
A very strong showing by Globe Trade Centre today, with an increase of €0.017 (3.620%) compared to yesterday's price.
Pros and Cons of Globe Trade Centre in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
B****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Globe Trade Centre vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Globe Trade Centre | 3.620% | 1.461% | 1.674% | -50.307% | -30.172% | -62.615% | -65.966% |
| Polski Holding Nieruchomosci | 0.000% | 0.253% | 0.506% | -8.945% | -5.476% | -13.696% | -36.378% |
| Deutsche Real Estate AG | 0.000% | 8.108% | 5.263% | 108.696% | 11.111% | 20.000% | -3.226% |
| Mobimo Holding AG | 0.270% | 1.230% | -0.403% | 11.261% | -4.633% | 60.043% | 60.043% |
News
NeuroPace Q2 Earnings Call Highlights
Key Points
- Interested in NeuroPace, Inc.? Here are five stocks we like better.
- Strong Q2 performance: Revenue rose 17% year over year to $22.8 million, led by 21.3% growth in RNS System
Jensen Huang Predicted Nvidia Would Collect $1 Trillion in Chip Sales Through 2027. Is Nvidia Still on Pace?
During the company's GTC conference in March, Nvidia (NASDAQ: NVDA) CEO Jensen Huang expressed confidence in the company's opportunity in the artificial intelligence (AI) chip market.
"We saw $500
NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data
Key Points
- Interested in NeuroPace, Inc.? Here are five stocks we like better.
- FDA did not approve NeuroPace’s application to expand the RNS System for medication-resistant idiopathic